- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00473577
Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
Two Phase, Open-Label, Sequential, Ascending Dose Study of the Tolerability, Safety, and Pharmacokinetics of CRA-024781 in Cancer Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Patients will receive a single oral dose of CRA-024781 one week before beginning intravenous dosing. Blood samples for pharmacokinetic and pharmacodynamic analysis will be collected on several occasions prior to the start of the intravenous treatment.
The intravenous treatment will consist of 3 consecutive days of CRA-024781 IV administered as a 2-hour IV infusion every 3 weeks in a 4 weeks cycle.
Assessment of the extent of disease will be performed every 8 weeks.
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60643
- University of Chicago
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- age ≥ 18 years
- histologically confirmed solid or hematologic malignancy that is refractory to standard therapy or for which no standard therapy exists
- estimated life expectancy > 12 weeks
- ECOG performance grade ≤ 2
- creatinine ≤ 1.5 X institutional upper limit of normal or creatinine clearance > 50 mL/min
- total bilirubin within institutional limits (unless elevated from documented Gilbert's syndrome)
- AST and ALT ≤ 2.5 X institutional upper limit of normal (≤ 5 x institutional upper limit of normal in the presence of liver metastases)
- platelet count ≥ 100,000/µL
- absolute neutrophil count (ANC) ≥ 1500/µL
- Hgb ≥ 9.0 g/dL
- patients with previously treated brain metastases who are not on corticosteroids are eligible
- effective contraceptive method (e.g., intrauterine device, oral contraceptive, or barrier device) must be used during the study by male and female patients of childbearing potential
- ability to understand and willingness to sign a written informed consent
Exclusion Criteria:
- patients who have had immunotherapy, chemotherapy, or radiotherapy within 4 weeks (within 6 weeks for nitrosoureas or mitomycin C) prior to study entry; study entry defined as first day of drug dosing
- patients who have undergone major surgery within 4 weeks prior to study entry
- patients who are receiving another investigational drug
- patients with active CNS metastases or leptomeningeal disease not controlled by prior surgery or radiotherapy
- uncontrolled illness including but not limited to: ongoing or active infection, symptomatic congestive heart failure (New York Heart Association Class III or IV heart failure), unstable angina pectoris, cardiac arrhythmia, and psychiatric illness that would limit compliance with study requirements
- risk factors for QTc prolongation and/or Torsade de Pointes
- patients with known HIV infection
- concurrent systemic hormonal therapy except: stable LHRH agonist therapy for prostate cancer; hormonal therapy (e.g., megestrol) for appetite stimulation; nasal, ophthalmic, and topical glucocorticoid preparations when appropriate; stable oral glucocorticoid and mineralocorticoid replacement for adrenal insufficiency; or oral contraceptives
- patients who have other medical or psychiatric illness or organ dysfunction which, in the opinion of the Investigator, would either compromise the patient's safety or interfere with the evaluation of the safety of the study agent
- pregnant or lactating women (female patients must have a negative serum pregnancy test within 7 days of study entry)
- patients who have previously received histone deacetylase inhibitors
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NON_RANDOMIZED
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PCYC 0401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
GlaxoSmithKlineRecruitingColonic Neoplasms | Neoplasms, ColonUnited States, Finland, France, Italy, Japan, Netherlands, Norway, Spain, Taiwan, United Kingdom, Australia, Belgium, Brazil, Germany, Greece, Sweden, Turkey, Canada, Korea, Republic of, Argentina, Hungary, Estonia, Portugal, Mexico, Pa...
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
University Health Network, TorontoPrincess Margaret Hospital, CanadaCompletedUterine Neoplasms | Prostatic Neoplasms | Cervix Neoplasms | Bladder NeoplasmsCanada
-
N.N. Petrov National Medical Research Center of...Active, not recruitingColonic Neoplasms MalignantRussian Federation
-
Peking University First HospitalShengli Oilfield Hospital; The Second Affiliated Hospital of Baotou Medical...Enrolling by invitationRectal Neoplasms MalignantChina
-
Cancer Institute and Hospital, Chinese Academy...CompletedRectal Neoplasms MalignantChina
Clinical Trials on CRA-24781
-
John StahlWashington University School of MedicineWithdrawnVentricular TachycardiaUnited States
-
Karolinska InstitutetNational Board of Institutional Care, SwedenRecruitingSubstance Use Disorders | Criminal BehaviorSweden
-
Pharmacyclics LLC.CompletedLymphoma | Leukemia | Multiple Myeloma | Hodgkin Disease | Non-Hodgkin's Lymphoma | LymphocyticUnited States
-
Varian, a Siemens Healthineers CompanyRecruiting
-
Pharmacyclics LLC.CompletedLymphoma | Lymphoma, Non-Hodgkin | Hodgkin DiseaseUnited States
-
IrisZorgRadboud University Medical CenterTerminated
-
Karolinska InstitutetRecruitingSubstance Use Disorders | Criminal BehaviorSweden
-
Pharmacyclics LLC.CompletedNeoplasms by Site | Multiple Myeloma | Hodgkin Disease | Leukemia, Lymphocytic, Chronic | Lymphoma, Non-hodgkinUnited States
-
Jason Robert GotlibNational Cancer Institute (NCI)TerminatedSystemic Mastocytosis | Mast Cell Leukemia | Aggressive Systemic MastocytosisUnited States
-
Xynomic Pharmaceuticals, Inc.RecruitingRenal Cell CarcinomaChina, Spain, United States, Italy, Korea, Republic of, Poland